Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mascitelli, L.
Right arrow Articles by John, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mascitelli, L.
Right arrow Articles by John, M.
(Chest. 2005;128:3084.)
© 2005 American College of Chest Physicians

Anemia and COPD

Luca Mascitelli, MD and Francesca Pezzetta, MD

Comando Brigata Alpina "Julia" Udine, Italy Ospedale di San Vito al Tagliamento San Vito al Tagliamento, Italy

Correspondence to: Luca Mascitelli, MD, Comando Brigata alpina "Julia", Sanitary Service, Via S. Agostino 8, Udine 33100, Italy; e-mail: lumasci{at}libero.it

To the Editor:

John and colleagues reported in a recent issue of CHEST (March 2005)1 a relatively high frequency of anemia in patients with COPD. However, they did not mention whether the studied population was in treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type 1 (AT1) receptor blockers.

Several observations suggested that an intact and activated renin-angiotensin system may be an important determinant of erythropoiesis,23 including a variety of clinical conditions such as hypertension, chronic renal insufficiency, heart failure, and COPD.4 Consequently, the assumption of ACE inhibitors and AT1 receptor blockers has been shown to reduce hemoglobin concentrations both in healthy subjects5 and in those with pathologic conditions.4678 Thus, therapy with ACE inhibitors and AT1 receptor blockers might have been a confounder in this study.1

References

  1. John, M, Hoernig, S, Doehner, W, et al (2005) Anemia and inflammation in COPD. Chest 127,825-829[Abstract/Free Full Text]
  2. Mrug, M, Stoppa, T, Julian, BA, et al Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997;100,2310-2314[Medline]
  3. Cole, J, Ertoy, D, Lin, H, et al Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin converting enzyme-deficient mice. J Clin Invest 2000;106,1391-1398[ISI][Medline]
  4. Marathias, KP, Agroyannis, B, Mavromoustakos, T, et al Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004;4,483-486[CrossRef][ISI][Medline]
  5. Griffing, GT, Melby, JC Enalapril (MK-421) and the white cell count and haematocrit [letter]. Lancet 1982;1,1361[Medline]
  6. Gaston, RS, Julian, BA, Diethelm, AG, Curtis, JJ Effects of enalapril on erythrocytosis after renal transplantation. Ann Intern Med 1991;115,954-955[Medline]
  7. Plata, R, Cornejo, A, Arratia, C, et al Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002;359,663-666[CrossRef][ISI][Medline]
  8. Ishani, A, Weinhandl, E, Zhao, Z, et al Angiotensin-converting-enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005;45,391-399[Abstract/Free Full Text]

Matthias John, MD, PhD

University Hospital Charité Berlin, Germany

Correspondence to: Matthias John, MD, PhD, Department of Pneumology, University Hospital Charité, Campus Mitte, Schumannstr. 20/21, 10098 Berlin, Germany; e-mail: matthias.john{at}charite.de

To the Editor:

The author of this comment mentioned that therapy with angiotensin-converting enzyme (ACE) inhibitors might be a confounder in interpreting the results of our study.1 In this patient population, 23 patients of the nonanemic group (88 patients) were treated with ACE inhibitors or angiotensin type-1 (AT1) receptor blockers. In the anemic group (13 patients), 3 patients received cotherapy with ACE inhibitors or receptor blockers. The {chi}2 test revealed no difference in the occurrence of ACE inhibitor therapy between both groups (p = 0.813). Therefore, we conclude that the reported prevalence of anemia in COPD patients in our study is not influenced by an ACE inhibitor or AT1 receptor blocker medication. Overall, it is an interesting issue that should be taken into consideration for future studies.

References

  1. John, MS, Hoernig, W, Doehner, C, et al Anemia and inflammation in chronic obstructive pulmonary disease. Chest 2005;127,825-829




This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mascitelli, L.
Right arrow Articles by John, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mascitelli, L.
Right arrow Articles by John, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS